IN171746B - - Google Patents

Info

Publication number
IN171746B
IN171746B IN907/CAL/90A IN907CA1990A IN171746B IN 171746 B IN171746 B IN 171746B IN 907CA1990 A IN907CA1990 A IN 907CA1990A IN 171746 B IN171746 B IN 171746B
Authority
IN
India
Prior art keywords
overindulgence
symptoms
treating
effective amount
acetaminophen
Prior art date
Application number
IN907/CAL/90A
Other languages
English (en)
Inventor
William Joseph Goldman
Thomas Neil Gates
Original Assignee
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23709269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN171746(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc
Priority to IN757CA1992 priority Critical patent/IN176327B/en
Publication of IN171746B publication Critical patent/IN171746B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
IN907/CAL/90A 1989-11-02 1990-10-29 IN171746B (da)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN757CA1992 IN176327B (da) 1989-11-02 1992-10-16

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43083789A 1989-11-02 1989-11-02

Publications (1)

Publication Number Publication Date
IN171746B true IN171746B (da) 1992-12-26

Family

ID=23709269

Family Applications (1)

Application Number Title Priority Date Filing Date
IN907/CAL/90A IN171746B (da) 1989-11-02 1990-10-29

Country Status (14)

Country Link
EP (1) EP0426479B1 (da)
JP (1) JPH03206052A (da)
KR (1) KR910009254A (da)
AT (1) ATE101515T1 (da)
AU (1) AU646230B2 (da)
CA (1) CA2028746C (da)
DE (1) DE69006684T2 (da)
ES (1) ES2057439T3 (da)
GR (1) GR1002097B (da)
IE (1) IE64953B1 (da)
IN (1) IN171746B (da)
NZ (1) NZ235877A (da)
PT (1) PT95753A (da)
ZA (1) ZA908775B (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0550083T3 (da) * 1991-12-06 1999-10-11 Glaxo Group Ltd Lægemidler til behandling af inflammatoriske tilstande eller til analgesi og indeholdende et NSAID og ranitidinbismuthcitra
AU4931693A (en) * 1992-09-29 1994-04-26 Mcneil-Ppc, Inc. Ibuprofen-h2 antagonist combinations
GB9221414D0 (en) * 1992-10-13 1992-11-25 Glaxo Group Ltd Pharmaceutical compositions
US5648355A (en) * 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
WO1998058637A1 (en) * 1996-06-20 1998-12-30 Mcneil-Ppc Acetaminophen and diphenhydramine analgesics
ZA975444B (en) * 1996-06-20 1998-12-21 Mcneil Ppc Inc Acetaminophen and meclizine hydrochloride analgesics
DE19801811B4 (de) * 1998-01-19 2004-12-23 Stada Arzneimittel Ag Pharmazeutische Zubereitung zur oralen Verabreichung
US20050220909A1 (en) 2004-03-30 2005-10-06 Theoharides Theoharis C Composition for protection against superficial vasodilator flush syndrome
US7799766B2 (en) 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US7906153B2 (en) 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
GB9911017D0 (en) * 1999-05-13 1999-07-14 Zeneca Ltd Pharmaceutical compositions
AU4198899A (en) * 1999-05-20 2000-12-12 Par Pharmaceutical, Inc. Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process
EP1189662A1 (en) * 1999-06-09 2002-03-27 Eli Lilly And Company Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
MXPA03007888A (es) * 2001-03-08 2003-12-04 Astrazeneca Ab Compuestos para tratamiento y prevencion de ulcera gastrica inducida por medicamentos.
ES2348710T5 (es) 2001-06-01 2014-02-17 Pozen, Inc. Composiciones farmacéuticas para el suministro coordinado de NSAID
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040185032A1 (en) * 2003-03-18 2004-09-23 David Burrell Compositions and methods for treating colic
US7923043B2 (en) 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
US7776873B2 (en) * 2005-12-01 2010-08-17 Yuhan Corporation Method for treating damage to gastric mucosa
HUE029444T2 (en) * 2008-01-04 2017-02-28 Schabar Res Ass Llc A composition containing an analgesic and an antihistamine
CA2736547C (en) 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
US9050275B2 (en) 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
US9176146B2 (en) 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
UA115139C2 (uk) 2011-12-28 2017-09-25 Поузен Інк. Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
US11331307B2 (en) 2020-07-15 2022-05-17 Schabar Research Associates, Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2105193B (en) * 1981-09-04 1984-09-12 Glaxo Group Ltd Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
US4522826A (en) * 1984-02-08 1985-06-11 Richardson-Vicks Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4757060A (en) * 1986-03-04 1988-07-12 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers

Also Published As

Publication number Publication date
ZA908775B (en) 1992-07-29
IE903946A1 (en) 1991-05-08
ATE101515T1 (de) 1994-03-15
DE69006684T2 (de) 1994-06-09
AU646230B2 (en) 1994-02-17
EP0426479B1 (en) 1994-02-16
JPH03206052A (ja) 1991-09-09
CA2028746C (en) 1995-12-26
DE69006684D1 (de) 1994-03-24
EP0426479A1 (en) 1991-05-08
KR910009254A (ko) 1991-06-28
CA2028746A1 (en) 1991-05-03
IE64953B1 (en) 1995-09-20
NZ235877A (en) 1992-09-25
PT95753A (pt) 1991-09-30
ES2057439T3 (es) 1994-10-16
GR900100786A (el) 1992-04-17
AU6568990A (en) 1991-05-09
GR1002097B (en) 1995-12-28

Similar Documents

Publication Publication Date Title
IN171746B (da)
BR9814327A (pt) Compostos de tiouréia e benzamida, composições e pro-cessos para tratamento ou prevenção de doenças infla-matórias e arteriosclerose
IL93556A0 (en) Stabilized nitric oxide-primary amine complexes useful as cardiovascular agents
NL300152I2 (nl) Preparaat dat een tramadolverbinding en aceetaminofen bevat en de toepassing ervan.
BR9806060A (pt) Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina.
DK1586322T3 (da) Sammensætninger indeholdende thalidomid og dextamethason til behandling af cancer
NO180583C (no) Arylsulfonamido-substituerte hydroksamsyrer, farmasöytiske preparater inneholdende forbindelsene og anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
NO924169L (no) Preparat omfattende et tramadolmateriale og et ikke-stereoid antiinflammatorisk legemiddel
GEP20002013B (en) Therapeutical Means
AP9701041A0 (en) Pyridylpyrrole compounds.
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
PT1057826E (pt) Derivados carboxamidicos dimericos substituidos processo para a sua preparacao e as composicoes farmaceuticas que os contem
NO954073D0 (no) Sammensetninger for inhibisjon, kontroll og regresjon av angiogenesen inneholdende hyaluronsyre og NSAID
DK0613687T3 (da) Anvendelse af pregnanderivat til behandling af tumorer
EP1419129A4 (en) USE OF BRANCHED CHAIN FATTY ACIDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN
WO2001003688A3 (en) Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds
HU229440B1 (en) Analgesic and anti-inflammatory compositions containing gox-2 inhibitors
AU8900498A (en) Compounds and pharmaceutical compositions thereof for eliciting analgesic effects
PL318539A1 (en) Inhibition of biosynthesis
ZA989356B (en) Pharmaceutical preparations
SE8504612L (sv) Analgetiska och antiinflammatoriska kompositioner innefattande difenhydramin och forfaranden for anvendning av dessa
ES8301230A1 (es) Un procedimiento para la preparacion de 1-fenil-5-amidotetrazoles.
BG100965A (en) New therapeutical injection-type analgetic pharmaceutical composition containing nimesulid (4-nitro, 2-phenoxyphenylmetanesulphonamide) for intramuscular administration and method for its preparation
IT8422445A0 (it) Composti antiinfiammatori ed analgesici, procedimento per laloro preparazione e relative composizioni farmaceutiche.
HUP9903183A2 (hu) Olanzapin alkalmazása fájdalomcsillapító hatású gyógyszerkészítmények előállítására